Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6039893 | 0.81 | HPGD (0.42) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6039784 | 0.77 | HPGD (0.46) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL861278 | 0.76 | USP2 (0.64) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL28060012 | 0.75 | HPGD (0.49) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| Acetic Acid SCHEMBL3768719 | 0.75 | USP2 (0.58) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL27893273 | 0.74 | USP2 (0.62) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| Methyl Alcohol SCHEMBL27463839 | 0.74 | USP2 (0.62) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL16612394 | 0.74 | USP2 (0.62) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| Iodide SCHEMBL15174787 | 0.74 | USP2 (0.62) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL28133562 | 0.74 | USP2 (0.62) | HPGDUSP2SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | disclosed |
| EP-2054417-A2 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB Pharma S.A. (BE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008020206-A2 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | MAPK15, MOK, MAPK14 | HPGD 1687/4885USP2 2676/4885SMN1; SMN2 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.